Selective MMP13 inhibitors

Matrix metalloproteinase 13–deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development

(2009) C. B. Little et al.   ARTHRITIS AND RHEUMATISM

OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?

(2009) M.-P. Hellio Le Graverand-Gastineau   OSTEOARTHRITIS AND CARTILAGE

Assessment of the renal toxicity of novel anti-inflammatory compounds using cynomolgus monkey and human kidney cells

(2009) Hongliang Cai et al.   TOXICOLOGY

Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer

(2008) Heikki Luukkaa et al.   ACTA OTO-LARYNGOLOGICA

High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate

(2008) Janelle L. Lauer-Fields et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognosis of invasive breast cancer

(2008) Bin Zhang et al.   BMC CANCER

Quinazolinones and Pyrido[3,4-d]pyrimidin-4-ones as Orally Active and Specific Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis

(2008) Jie Jack Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

A critical role for collagen II in cartilage matrix degradation: Collagen II induces pro-inflammatory cytokines and MMPs in primary human chondrocytes

(2008) Andreas R. Klatt et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity

(2008) Morten A Karsdal et al.   ARTHRITIS RESEARCH & THERAPY

Drug Insight: aggrecanases as therapeutic targets for osteoarthritis

(2008) Amanda J Fosang et al.   Nature clinical practice. Rheumatology

Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?

(2008) Gillian Murphy et al.   Nature clinical practice. Rheumatology